Cargando…

Pharmacogenetic Associations Between Atazanavir/UGT1A1*28 and Efavirenz/rs3745274 (CYP2B6) Account for Specific Adverse Reactions in Chilean Patients Undergoing Antiretroviral Therapy

Background: Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, and atazanavir (ATV), a protease inhibitor, are drugs widely used in antiretroviral therapy (ART) for people living with HIV. These drugs have shown high interindividual variability in adverse drug reactions (ADRs). UGT1A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poblete, Daniela, Bernal, Fernando, Llull, Gabriel, Archiles, Sebastian, Vasquez, Patricia, Chanqueo, Leonardo, Soto, Nicole, Lavanderos, María A., Quiñones, Luis A., Varela, Nelson M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170096/ https://www.ncbi.nlm.nih.gov/pubmed/34093191 http://dx.doi.org/10.3389/fphar.2021.660965

Ejemplares similares

Distribution of alleles, genotypes and haplotypes of the CYP2B6 (rs3745274; rs2279343) and CYP3A4 (rs2740574) genes in the Malian population: Implication for pharmacogenetics
por: Kassogue, Yaya, et al.
Publicado: (2021)

Investigating the CYP2B6 rs3745274 and rs3211371 Polymorphisms in Methadone-Responder and Non-Responder Addicts in Iran
por: Aghabozorg Afjeh, Sara Sadat, et al.
Publicado: (2021)

Atazanavir/efavirenz/lamivudine: Covid-19: case report
Publicado: (2021)

Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation
por: Leger, Paul, et al.
Publicado: (2018)

Pharmacogenetics of ugt genes in North African populations
por: Gaibar, M., et al.
Publicado: (2018)

Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes
por: Mukonzo, Jackson K., et al.
Publicado: (2014)

Pharmacogenetics of CYP2A6, CYP2B6, and UGT2B7 in the Context of HIV Treatments in African Populations
por: Ford, Graeme R., et al.
Publicado: (2022)

Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy
por: Estrada, Vicente, et al.
Publicado: (2014)

Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV‐Infected Subjects With Aging Biomarkers
por: Dumond, JB, et al.
Publicado: (2016)

Drug‐drug interaction of atazanavir on UGT1A1‐mediated glucuronidation of molidustat in human
por: van der Mey, Dorina, et al.
Publicado: (2020)

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens
por: Ganesan, Anuradha, et al.
Publicado: (2009)

HIV-Tat Exacerbates the Actions of Atazanavir, Efavirenz, and Ritonavir on Cardiac Ryanodine Receptor (RyR2)
por: Alomar, Fadhel A., et al.
Publicado: (2022)

Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele
por: Panagopoulos, Periklis, et al.
Publicado: (2017)

Role of the UGT2B17 deletion in exemestane pharmacogenetics
por: Luo, Shaman, et al.
Publicado: (2017)

The Relationship of UGT2B15 Pharmacogenetics and Lorazepam for Anxiety
por: Ching, Nathan R, et al.
Publicado: (2018)

Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients
por: Contreras-Castillo, Stephania, et al.
Publicado: (2021)

Functionally Significant Coumarin-Related Variant Alleles and Time to Therapeutic Range in Chilean Cardiovascular Patients
por: Rojo, Mario, et al.
Publicado: (2020)

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants
por: Mollan, Katie R, et al.
Publicado: (2017)

Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the UGT1A1*28 allele
por: Naidoo, Anushka, et al.
Publicado: (2017)

A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study
por: Roco, Angela, et al.
Publicado: (2020)

Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals
por: Cain, Lauren E., et al.
Publicado: (2016)

Prevalence and correlates of persistent intracellular HIV transcription in individuals on efavirenz versus atazanavir-based regimens: A prospective cohort study
por: Pilalas, Dimitrios, et al.
Publicado: (2018)

Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria
por: Nwogu, Jacinta N., et al.
Publicado: (2021)

Pharmacogenetics in Psychiatry: Perceived Value and Opinions in a Chilean Sample of Practitioners
por: Undurraga, Juan, et al.
Publicado: (2021)

The clinical application of UGT1A1 pharmacogenetic testing: Gene-environment interactions
por: Marques, Sara Correia, et al.
Publicado: (2010)

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1
por: de With, Mirjam, et al.
Publicado: (2023)

Atazanavir nephrotoxicity
por: Hara, Masaki, et al.
Publicado: (2015)

Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia
por: Vardhanabhuti, Saran, et al.
Publicado: (2015)

Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis
por: Du, Pengqiang, et al.
Publicado: (2019)

Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir
por: Samuel, Miriam, et al.
Publicado: (2014)

Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis
por: Agyemang, Nana, et al.
Publicado: (2023)

Crystal Structure of CYP2B6 in Complex with an Efavirenz Analog
por: Shah, Manish B., et al.
Publicado: (2018)

CYP46A1-dependent and independent effects of efavirenz treatment
por: Mast, Natalia, et al.
Publicado: (2020)

97856 Implementation of DPYD and UGT1A1 pharmacogenetic testing to guide chemotherapy dosing
por: Varughese, Lisa A., et al.
Publicado: (2021)

Characterization of CYPs and UGTs Involved in Human Liver Microsomal Metabolism of Osthenol
por: Cho, Pil Joung, et al.
Publicado: (2018)

UGT1A1 (TA)(n) Promoter Genotype: Diagnostic and Population Pharmacogenetic Marker in Serbia
por: Vukovic, M, et al.
Publicado: (2018)

Pharmacogenetics of uridine diphosphate glucuronosyltransferase (UGT2B7) genetic polymorphism on valproic acid pharmacokinetics in epilepsy
por: Munisamy, Murali, et al.
Publicado: (2014)

Prospective evaluation of bone markers, parathormone and 1,25-(OH)(2 )vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
por: Focà, Emanuele, et al.
Publicado: (2012)

Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
por: Muche Belete, Abebe, et al.
Publicado: (2021)

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype-dependent
por: Michaud, Veronique, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3ua679bq0a3080vme3sfeeu1je